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The structure and biosynthesis of heinamides
A1–A3 and B1–B5, antifungal members of the
laxaphycin lipopeptide family†
Lassi Matti Petteri Heinilä, a David Peter Fewer, a Jouni Kalevi Jokela, a
Matti Wahlsten, a Xiaodan Ouyang, a Perttu Permi,b,c Anna Jortikka a and
Kaarina Sivonen *a
Laxaphycins are a family of cyclic lipopeptides with synergistic antifungal and antiproliferative activities.
They are produced by multiple cyanobacterial genera and comprise two sets of structurally unrelated 11-
and 12-residue macrocyclic lipopeptides. Here, we report the discovery of new antifungal laxaphycins
from Nostoc sp. UHCC 0702, which we name heinamides, through antimicrobial bioactivity screening.
We characterized the chemical structures of eight heinamide structural variants A1–A3 and B1–B5. These
variants contain the rare non-proteinogenic amino acids 3-hydroxy-4-methylproline, 4-hydroxyproline,
3-hydroxy-D-leucine, dehydrobutyrine, 5-hydroxyl β-amino octanoic acid, and O-carbamoyl-homoser-
ine. We obtained an 8.6-Mb complete genome sequence from Nostoc sp. UHCC 0702 and identified the
93 kb heinamide biosynthetic gene cluster. The structurally distinct heinamides A1–A3 and B1–B5 variants
are synthesized using an unusual branching biosynthetic pathway. The heinamide biosynthetic pathway
also encodes several enzymes that supply non-proteinogenic amino acids to the heinamide synthetase.
Through heterologous expression, we showed that (2S,4R)-4-hydroxy-L-proline is supplied through the
action of a novel enzyme LxaN, which hydroxylates L-proline. 11- and 12-residue heinamides have the
characteristic synergistic activity of laxaphycins against Aspergillus flavus FBCC 2467. Structural and
genetic information of heinamides may prove useful in future discovery of natural products and drug
development.
Introduction
Cyanobacteria produce a wide range of bioactive natural pro-
ducts with unusual structures and potent bioactivity.1,2
Knowledge of natural product chemical structures and biosyn-
thetic mechanisms can facilitate their use in the pharma-
ceutical industry as new active compounds3–5 and provide
insights into their ecological role.6 Laxaphycins are cyanobac-
terial natural products with two distinct macrocycles, 11- and
12-residue types, which act in synergy to produce antiprolifera-
tive and antifungal activities.7,8 Laxaphycins include character-
istic non-proteinogenic amino acids, including 3-hydroxy-D-
leucine (OHLeu), 3-hydroxy-D-asparagine (OHAsn), dehydrobu-
tyrine (Dhb), and (2S,4R)-4-hydroxyproline ((2S,4R)-4-
OHPro).9,10 Altogether 17 variants of 11-residue laxaphycins
and 23 variants of 12-residue laxaphycins have been described
from a broad range of cyanobacteria (Table S1†). Although 11-
and 12-residue types are both found in most producer strains,
there are reports of strains for which only one type of the com-
pound is reported.11,12
In an earlier study, we described the biosynthetic pathway
of scytocyclamides, which belong to the laxaphycin peptide
family.10 This pathway includes a shared initiating fatty-acyl
AMP ligase (FAAL) and a polyketide synthase (PKS) module
that branches with two non-ribosomal peptide synthetase
(NRPS) pathways to produce the two distinct 11- and
12-residue compounds.10 Scytocyclamides are produced by
Scytonema hofmannii PCC 7110.
The aim of this study was to identify and describe new anti-
fungal compounds from cyanobacteria. Members of the
genera Candida and Aspergillus can cause invasive infections
in humans, typically in immunocompromised patients.13,14
Only a few chemical families of antimicrobials are currently
used to treat fungal infections, and fungal resistance to these
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compounds is growing.13–15 Cyanobacteria are known produ-
cers of antifungal compounds such as laxaphycins, hassalli-
dins, nostofungicidine, and cryptophycins, which could be
used as antifungal drug leads.7,16–19
Here, we identified novel members of the laxaphycin family
of natural products, heinamides, through bioactivity-guided
fractionation of Nostoc sp. UHCC 0702 extracts. Heinamides
have antifungal activity that inhibit the growth of Aspergillus
flavus FBCC 2467 with synergistic effect between 11- and
12-residue type heinamides. We describe the chemical struc-
tures of heinamides A1–A3 and B1–B5 and identified the heina-
mide biosynthetic pathway. While the biosynthetic pathway is
generally similar to the previously described scytocyclamide
pathway, the differences provide a broader view of the laxa-
phycin biosynthesis pathways. The heinamide biosynthetic
pathway encodes enzymes for the production of the unusual
amino acids (2S,4R)-4-OHPro and 3-hydroxy-4-methylproline
(OHMePro), which appear in heinamide structures. The action
of the proline hydroxylase LxaN from Nostoc sp. UHCC 0702 was
shown through heterologous expression. A homolog of LxaN
was found also in the genome of S. hofmannii PCC 7110, a pro-
ducer of scytocyclamides, which also contain (2S,4R)-4-OHPro.
Experimental
Strains
Cyanobacterial strains used in this study were Nostoc sp.
UHCC 0702, isolated from the Finnish freshwater lake
Villähteen Kukkanen (60°57′19.4″N 25°53′02.4″E) in 19.8.2013,
and S. hofmannii PCC 7110, which originated from a limestone
cave in Bermuda.
Antimicrobial screening
Nostoc sp. UHCC 0702 was grown in 250 mL of Z8 medium at
20–21 °C with photon irradiation of 15 µmol m−2 s−1.
Erlenmeyer flasks of 500 mL were used with 250 mL of
medium, with constant sterilized air bubbling for 3–5 weeks.
The biomass was collected by decanting excess media and cen-
trifugation at 8000g for 5 min. The biomass was frozen at
−80 °C and freeze-dried with a CHRIST BETA 2–8 LSC plus
freeze drier with a LYO CUBE 4–8 chamber. A total of 100 mg
of freeze-dried Nostoc sp. UHCC 0702 biomass was extracted
with 1 mL of methanol and glass beads (0.5 mm glass beads,
Scientific Industries Inc, USA) using a FastPrep cell disrupter
at 6.5 m s−1 two times for 25 s with a resting time of 5 min
between runs. The samples were centrifuged at room tempera-
ture at 8000g for 5 min. The supernatant was collected and
extraction of the biomass was repeated with 1 mL of methanol.
The 2 mL combined supernatant was stored at −20 °C.
Antimicrobial activity screening was performed using 17
strains of fungi and bacteria (Table S2†). A total of 50 µL of
cell extract, 50 µl of methanol (negative control) and 10 µL nys-
tatin (5 mg mL−1, Nystatin, Streptomyces noursei, EMD
Millipore Corp, Germany) or 10 µL ampicillin (50 mg mL−1 in
70% ethanol, Ampicillin sodium salt, Sigma, Israel) were
placed directly on the agar surface prior to inoculation with an
indicator strain. Nystatin was used as a positive control for
fungal assays while ampicillin was used as a positive control
for bacterial assays. Solvents of the extract and controls were
allowed to evaporate, leaving the solids diffused in the agar.
Inoculant was prepared by growing fungi for 2–14 days on
potato dextrose agar (PDA) media at 28 °C and bacteria for 2
days on brain heart infusion (BHI) agar at 37 °C. Inoculant cell
mass was transferred with a cotton swab from the agar to 3 mL
of sterile 5 M NaCl solution, or sterile water in the case of
A. flavus. Solution was spread on the assay plate with a fresh
cotton swab. Fungal plates were incubated at 28 °C and bac-
terial plates at 37 °C for 2 days and examined for the presence
of inhibition zones.
Disc-diffusion assays were performed with purified heina-
mide for more quantitative analysis of bioactivity. Paper discs
(Blank monodiscs, Abtek biologicals Ltd, UK) were prepared
with methanol solutions of the peptides, methanol as negative
control, and nystatin as positive control. A. flavus inoculum
was prepared as previously and spread on the plate. Disks were
placed on agar, the plates were incubated at 28 °C for 2 days,
and examined for the presence of inhibition zones.
Purification of heinamides
Mass cultures were grown in modified Z8 medium without
added nitrogen at 20–21 °C with photon irradiation of 15 µmol
m−2 s−1. Five-liter Erlenmeyer flasks were used with 2.7 L of
medium, with constant sterilized air bubbling for 3–5 weeks.
Cells were collected by decanting excess media and centrifu-
gation at 8000g for 5 min. The cells were frozen at −80 °C and
freeze-dried as described earlier.
A total of 30 mL of methanol was used per 1 g of dry cells.
Cells were homogenized with a Heidolph Silentcrusher M at
20 000 rpm for 30 s. The solution was centrifuged 10 000g for
5 min and supernatant was collected. The extraction was
repeated with 30 mL of methanol using the cell pellet.
Chomatorex (Fuji-Davison Chemical Ltd, Aichi, Japan) chrom-
atography silica ODS powder (10 mL) was added to the super-
natant pool and the mixture was dried with a rotary evaporator
Büchi Rotavapor R-200 at 30 °C. Solid phase extraction (SPE)
was performed with Phenomenex SPE strata SI-1 silica 5 g per
20 mL column, preconditioned with 20 mL isopropanol and
20 mL of heptane. Silica ODS powder with the dry extract was
added on top of the column and extracted with heptane, ethyl
acetate, acetone, acetonitrile, and methanol, 40 mL each, with
every fraction collected individually. Fractions were dried with
a nitrogen gas flow and re-dissolved in 1 mL of methanol for
bioactivity assays.
The active methanol fraction was further fractionated
with an Agilent 1100 Series liquid chromatograph with
Phenomenex Luna C18(2) (150 × 10 mm, 100 Å) column.
Sample was injected in 100 µL batches and eluted with aceto-
nitrile/isopropanol 1 : 1 (solvent B) and 0.1% HCOOH (solvent
A) with initial isocratic stage of 40% solvent B in A for 15 min,
followed by a linear gradient of solvent B from 40% to 100% in
10 min with a flow rate of 3 mL min−1. Four heinamide frac-
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tions were collected, dried with nitrogen flow, and weighed.
Fraction 1 contained heinamides B1 and B2 (1 : 1), fraction 2
contained heinamide B1, fraction 3 contained heinamides A1,
B3, and B4 (7 : 2 : 1) and fraction 4 contained heinamide A2. To
further separate the products, fraction 3 was treated with an
additional HPLC run with isocratic conditions of 41% solvent
B in solvent A for 30 min with flow rate of 3 mL min−1 using
the same column. Fraction 3 was thus separated to fractions
3a and 3b containing heinamides B3 + B4 and A1, respectively.
Heinamides A3 and B5 were not purified due to low pro-
duction levels.
Amino acid analysis
To elucidate the stereochemistry of the eight heinamide struc-
tural variants, amino acid analysis was performed with the
Marfey method as described before20 with the isolated heina-
mides A1–A2 and B1–B4. The reagents 1-fluoro-2,4-dinitrophe-
nyl-5-L-alanine amide (FDAA), 1-fluoro-2,4-dinitrophenyl-5-L-
leucine amide (L-FDLA), and fluoro-2,4-dinitrophenyl-5-D-leucine
amide (D-FDLA) were used with reference amino acids L-Ser,
D-Ser, L-Hse, D-Hse, L-Glu, D-Glu, L-Thr, D-Thr, L-Val, D-Val, D-Pro,
L-Pro, L-Tyr, D-Tyr, D-allo-Thr, L-Leu, D-Leu, L-Ile, D-Ile, D-allo-Ile, L-
allo-Ile, D-Phe, L-Phe, (2S,4S)-4-hydroxy-Pro, (2R,4S)-4-hydroxy-
Pro, (2S,4R)-4-hydroxy-Pro, L-Ser, D-Ser, (Sigma, Switzerland),
N-methyl-L-Ile (hydrochloride, ABCR, Germany), L-allo-Thr (ICN
Biomedicals, USA), (2R,4R)-4-hydroxy-Pro (Aldrich, USA), and
(3S)- and (3R)-3-amino octanoic acid (ABCR, Germany).
Amino acid feeding experiment
Nostoc sp. UHCC 0702 and S. hofmannii PCC 7110 were culti-
vated in the presence of different Pro variants and hypoth-
esized OHMePro synthesis intermediates to investigate if they
are incorporated in the laxaphycin structures. Nostoc sp. UHCC
0702 was grown on Z8 media and S. hofmannii PCC 7110 was
grown on Z8 media without added nitrogen. The media were
modified by adding (2S,4S)-4-methyl-proline, (2R,4R)-4-methyl-
proline, (2S,4R)-4-methyl-proline, (ABCR, Germany), (2S,4S)-4-
hydroxyproline (Sigma, USA), (2S,4R)-4-hydroxyproline (Sigma,
Japan), or L-Leu (Sigma, Switzerland) to concentrations of
10 µM. Racemic OHLeu was used at 40 µM concentration.
Unaltered medium was used in control cultivation. Three repli-
cates of each cultivation were grown and analyzed. The bac-
teria were grown in 100 mL Erlenmeyer flasks in 40 mL of
medium for 17 days at 20–21 °C with photon irradiation of
15 µmol m−2 s−1. Cells were collected by centrifugation at
8000g for 5 min. Cells were frozen to −80 °C and freeze-dried.
Freeze-dried biomass was weighed and extracted with 0.5 mL
methanol and glass beads (0.5 mm glass beads, Scientific
Industries Inc, USA) using a FastPrep cell disrupter two times
for 25 s at a speed of 6.5 m s−1. Samples were centrifuged at
room temperature at 10 000g for 5 min and supernatant was
collected for LC-MS analysis.
Stable isotope labeling
Nostoc sp. UHCC 0702 was labelled with 15N in a nitrogen-free
atmosphere in Z8 growth medium containing 15N-urea as the
sole source of nitrogen. The medium was bubbled with nitro-
gen-free argon with 20.9% O2 and 0.45% CO2 (quality 5.7; AGA
Gas Ab, Sweden). The strain was grown for 21 days at 20 °C
under photon irradiation of 15 µmol m−2 s−1. The biomass
was collected and freeze dried. A total of 100 mg of the dried
cells were extracted with methanol as described earlier and
analyzed with LC-MS.
LC-MS
Freeze-dried bacterial cells were extracted with methanol as
described earlier. Extracts and isolated heinamide fractions
dissolved in methanol were analyzed with UPLC-QTOF
(Acquity I-Class UPLC-SynaptG2-Si, Waters Corp., Milford, MA,
USA) equipped with a Kinetex® C8 column (2.1 × 50 or
100 mm, 1.7 µm, 100 Å, Phenomenex, Torrance, CA, USA)
injected with 0.5 or 1 µL of sample and eluted at 40 °C with
0.1% HCOOH in water (solvent A) and acetonitrile/isopropanol
(1 : 1, +0.1% HCOOH, solvent B) at a flow rate of 0.3 mL min−1.
Different solvent gradients were used (Table S3†).
QTOF was calibrated using sodium formate and
Ultramark® 1621, which gave a calibrated mass range from
m/z 91 to 1921. Leucine Enkephalin was used at 10 s intervals
as a lock mass reference compound. Mass spectral data were
accumulated in positive electrospray ionization resolution
mode. In MS/MS mode, Trap Collision Energy Ramp pro-
ceeded from 40.0 eV to 70.0 eV.
NMR spectroscopy
NMR spectra were obtained using a Bruker Avance III HD
800 MHz NMR spectrometer equipped with the TCI 1H, 13C,
15N triple resonance cryoprobe. Data were collected at 30 °C in
DMSO-d6. In addition to
1H and broadband-decoupled 13C
experiments, we employed two-dimensional TOCSY (TOtal
Correlation SpectroscopY), DQF-COSY (Double Quantum
Filtered COrrelation SpectroscopY), and EASY-ROESY (Efficient
Adiabatic SYmmetrized Rotating-frame Overhauser Effect
SpectroscopY)21 experiments, and 13C HSQC, 15N HSQC, edited
13C HSQC (heteronuclear Single Quantum Coherence), and 13C
HMBC (Heteronuclear Multiple Bond Correlation) experiments
for the assignment of 1H, 13C, and 15N chemical shifts. The 2D
TOCSY was acquired with isotropic mixing time of 60 ms (10
kHz RF field). The mixing time for 2D ROESY experiment was
200 ms (RF field strength 4 kHz). For observing long-range H–C
connectivities, the 13C HMBC experiment was measured using
nJCH transfer time optimized for 8 Hz couplings. NMR experi-
ment parameters are presented in Table S4.†
Genome sequencing and gene cluster analysis
Cultures were grown in 250 mL of modified Z8 medium
lacking a source of combined nitrogen at 20–21 °C with
photon irradiation of 15 µmol m−2 s−1. Half-liter Erlenmeyer
flasks were used with 250 mL of medium, with constant steri-
lized air bubbling for 3 weeks. The fresh Nostoc sp. UHC 0702
cells were disrupted by bead beating in GOS buffer and DNA
was extracted with the phenol–chloroform method as pre-
viously described.20 Sequencing of the extracted DNA was per-
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formed with PacBio RSII and MGI DBNSeq-G400 sequencing
and assembled with HGAP3 (smrtportal 2.3.0).
The Nostoc sp. UHCC 0702 complete genome data was ana-
lyzed with AntiSMASH 5.022 and AntiSMASH 4.123 to identify
the lxa biosynthetic gene cluster. BLASTp and CDD database
searches were used to assign a predicted function to the pro-
teins encoded in the lxa biosynthetic gene clusters from the
Nostoc sp. UHCC 0702 and S. hofmannii PCC 7110 genomes.
The condensation domain of LxaC13 was analyzed with
Natural Product Domain Seeker (NaPDoS)24 and compared
with other known Dhb-related condensation domains LxaC13,
HasO2, NdaA1, and PuwF2, which are involved in the biosyn-
thesis of scytocyclamides,10 hassalladins,25 nodularins,20 and
puwainaphycins,26 respectively.
Heterologous expression of lxaN gene
The function of LxaN, a putative proline 4-hydroxylase, was
tested through heterologous expression in Escherichia coli
BL21(DE3). LxaN was expected to hydroxylate available Pro in
the E. coli cells. Plasmid constructs with the lxaN gene were
prepared and transformed to E. coli, and amino acid analysis
was performed to detect 4-OHPro in the transformed cells.
Genomic DNA was extracted from Nostoc sp. UHCC 0702 as
previously described. The lxaN gene was amplified by PCR
with primers LxaN-F (5′-gtggtggtgctcgagtgcggccgcaTTAAATAA-
GAACTTTGTCCAATAG-3′) and LxaN-R (5′-ggacagcaaatgggtcgcg-
gatccgATGTCCTATACCAATCAAAC-3′). The vector pET28a (+)
was digested with restriction enzymes EcoRI and HindIII
(Promega, USA). The lxaN gene was inserted into pET28a (+)
using the NEBuilder® HiFi DNA Assembly Cloning Kit (New
England BioLabs, USA) to create plasmid pET28a-LxaN. To allow
inducible expression, the lxaN gene was placed behind a T7 pro-
moter and lac operator. The plasmid pET28a-LxaN was trans-
formed into E. coli BL21 (DE3). A negative control was prepared
by transforming an empty pET28a plasmid into E. coli BL21
(DE3). Clones were selected by using LB agar plates containing
50 μg mL−1 kanamycin, 1 g 100 mL−1 arabinose, and 1 g
100 mL−1 glucose. Three transformants and a negative control
were transferred to liquid LB medium with 50 μg mL−1 kanamy-
cin and 1 g 100 mL−1 glucose and incubated at 37 °C overnight
with shaking (170 rpm). Aliquots of these primary cultures were
used to inoculate 10 mL of fresh LB medium supplemented
with selective antibiotics, 1 g 100 mL−1 arabinose, and
1 g 100 mL−1 glucose. The cultures were incubated at 37 °C with
shaking at 170 rpm until OD600 of 0.6 was achieved. The cultures
were induced with 0.1 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) and incubated at 18 °C for 48 h with shaking (200 rpm).
Biomass was collected from the growth culture by centrifu-
gation and the supernatant was discarded. The biomass was
frozen at −80 °C in screw-cap tubes. To extract biomass,
200 μL of 0.5 mm glass beads (Scientific Industries Inc, USA)
and 1 mL 100% methanol were added into the tube. The
mixture was homogenized by using Fastprep-24 twice for 20
seconds at a speed of 6 m s−1. Cell debris was pelleted by cen-
trifugation at 13 400g for 5 min. Supernatant was transferred
into new tubes and dried with nitrogen gas flow. Amino acid
analysis was performed with Marfey’s method as previously
described with UPLC-QTOF mass spectrometry,20 using refer-
ence amino acids (2S,4S)-4-hydroxyproline, (2S,4R)-4-hydroxy-




A methanol extract of Nostoc sp. UHCC 0702 inhibited the
growth of A. flavus FBCC 2467. The other tested fungal and
bacterial strains were not affected by the extract.
Structure of heinamides
Eight peptides belonging to the laxaphycin family were identi-
fied from Nostoc sp. UHCC 0702 and named heinamides A1–
A3 and B1–B5 (Fig. 1). Heinamides A1–A3 are 11-residue laxa-
phycins and heinamides B1–B5 are 12-residue laxaphycins.
The 11-residue heinamides follow the amino acid sequence
Aoa1-Ser2-Dhb3-((2S,4R)-4-OHPro/Pro)4-Ser5-Tyr6-Leu7-Ile8-Phe9-
((2S,4R)-4-OHPro/Pro)10-Gly11; the difference between variants
was the hydroxylation of Pro4,10. The 12-residue heinamides
have the amino acid sequence (Aoa/5-OH-Aoa)1-Ile2-OHLeu3-
(O-carbamoyl-Hse)4-Leu5-Gln6-(N-Me-Ile)7-OHHse8-Val9-(OHMePro/
Pro/4-MePro)10-Tyr11-Thr12, where the differences between var-
iants is in the hydroxylation of the octanoic acid1 and hydroxy-
lation and methylation of the Pro10. The stereochemistry of the
compounds is derived from stereospecific amino acid analysis
(Table S11†) and NMR.
The methanol extract from Nostoc sp. UHCC 0702 was ana-
lyzed with UPLC-QTOF to determine the initial heinamide
structures. Cultivation on 15N-containing medium and com-
parison of the mass data of 15N-labeled and unlabeled com-
pounds showed the presence of 11 nitrogen atoms in
11-residue heinamides A1–A3 and 14 nitrogen atoms in
12-residue heinamides B1–B5 (Table S5, Fig. S2†). The product
ion spectra of protonated heinamides consisted of many
evenly intense ions, which is typical for some cyclic peptides
(Fig. S3–S6†). The best continuous data for amino acid sequen-
cing started as expected from the amino acids next to the Pro
N-terminus (red markings in Fig. S3 and S4†). The structure of
heinamides A3, B4 and B5 is proposed solely on the basis of
analyses of their LC MS/MS data. The structures assigned by
LC-MS were consistent with those assigned using NMR. 1H,
13C, DQF-COSY, TOCSY, EASY-ROESY, 13C HSQC, edited 13C
HSQC, 15N HSQC, and 13C HMBC NMR spectra were obtained
from the purified heinamides A2 and B2 and heinamide mix-
tures A1 : B3 : B4 (7 : 2 : 1) and B1 : B2 (1 : 1). NMR spectra are
presented in Fig. S7–S10† and numerical data with COSY,
ROESY, and HMBC correlations in Tables S6–S10.† COSY,
HMBC, and ROESY uninterrupted correlation chain specified
the subunit sequences in both 11-residue (HA A1) and
12-residue (HA B2) heinamides (Fig. S11 and S12†).
Heinamide structures were in good agreement with previously
described laxaphycin common structural features (Table S1†).
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In heinamides A1–A3, the only new element was (2S,4R)-4-
OHPro or L-Pro in position 10. Two different ppm value sets
for 4-OHPro were present for HA A1. In amino acid analysis
(2S,4R)-4-OHPro was the only 4-OHPro enantiomer present of
the four possible alternatives (Tables S6 and S11†). More new
elements were found in 12-residue heinamides B1–B5. The
hydroxy group in the β-amino octanoic acid1 has not been
described earlier in laxaphycins, but COSY, HSQC, and
HMBC correlations show the presence of a methine (δH =
3.46, δC = 66.2 ppm) group in position 5, which is most prob-
ably bonded to oxygen in HA B1 (Fig. S9F, I and N and S12†).
In many 12-residue laxaphycins, Leu5 is hydroxylated but not
in heinamides according to NMR (Fig. S9E, L and M†). In
previously described 12-residue laxaphycins, the amino acid
in position 8 has almost exclusively been 3-OHAsn. However,
the amino acid is 3-hydroxy-homoserine in heinamides B1–
B5 (Tables S8–S10, Fig. S9 and S10†). Lastly, NMR data
showed another Hse is in position 4 in 12-residue heina-
mides. Furthermore, COSY, HSQC, and HMBC correlations
showed that this subunit was actually O-carbamoylated
(Fig. S9, especially frame O, Tables S8–S10†). Isobaric 3- or
4-OHGln were ruled out as the C3 and C4 were methylenes
according the edited 13C-HSQC (Fig. S9,† frame I). Product
ion spectra of protonated heinamides B1–B5 show the loss of
the carbamoyl group as carbamic acid (61.02 Da) until the
loss of the O-carbamoyl-Hse4 subunit itself (Fig. S4–S6†). No
12-residue heinamide without an O-carbamoyl group in Hse
was found.
Antifungal activity
After fractionation of the extract and identification of the pro-
ducts, disc diffusion assays were performed with the purified
compounds. Inhibition of fungal growth was observed with
peptides of a single laxaphycin type as a hazy inhibition zone.
Synergy was observed between 11- and 12-residue compounds
as a clear inhibition zone (Fig. 2).
Predicted heinamide biosynthetic pathway from Nostoc
sp. UHCC 0702
We sequenced the complete genome of Nostoc sp. UHCC 0702
(GenBank accession number CP071065). The genome is a
Fig. 1 Chemical structures of heinamides and relative intensities of their MS signals (%), purified from Nostoc sp. UHCC 0702.
Fig. 2 Inhibition of growth of Aspergillus flavus by heinamides.
Heinamide A2 (200 µg), heinamide B1 + B2 (200 µg), and heinamide A2
with B1 + B2 (100 µg + 100 µg). A mix of B1 and B2 was used due to
imperfect purification of the compounds, with the fraction including
both B1 and B2 (1 : 1). Individual compounds exhibit weak inhibition and
synergistic activity is seen when combining 11- and 12-residue molecules.
Organic & Biomolecular Chemistry Paper
























































































single 8587 404 bp circular chromosome without extrachromo-
somal elements. Sequence coverage with PacBio RSII was 90x
and with MGI DBNSeq-G400 46x. Bioinformatics analysis with
AntiSMASH identified 13 putative NRPS/PKS pathways.
Comparison with the S. hofmannii PCC 7110 lxa biosynthetic
gene cluster and chemical structures of the identified heina-
mides confirmed the presence of a lxa biosynthetic gene
cluster in Nostoc sp. UHCC 0702 (Fig. 3).
The cluster is 93 kb long and encodes 13 open reading
frames annotated as ORF1–2, lxaI1, lxaJ1, lxaK1, lxaA2, ORF3,
lxaB, lxaC1, lxaE, lxaF, lxaG, and lxaM (Fig. 3, Table 1). lxaC1
is an NRPS with adenylation domain binding pockets match-
ing the amino acid sequence of 11-residue heinamides
(Table S12†). lxaC1 is flanked with PKSs lxaB and lxaE fol-
lowed by cupin-like domains lxaFGM (Fig. 3, Table 1). The
Nostoc sp. UHCC 0702 genes lxaI1, lxaJ1, and lxaK1 adenyla-
tion domain binding pockets match the amino acid sequence
of 12-residue heinamides (Fig. 3, Table S12†). The position of
epimerase domains in the lxa biosynthetic enzymes match the
positions of D-amino acids in the elucidated structures (Fig. 1
and 3). Laxaphycin biosynthesis is predicted to be initiated by
an activating enzyme lxaA with FAAL and ACP domains
(Fig. 3). However, such an enzyme was not encoded in the
Nostoc sp. UHCC 0702 lxa biosynthetic gene cluster. Instead,
an ACP in the cluster with 41% sequence identity in BLASTp to
the ACP domain of LxaA was identified and designated LxaA2
(Fig. 3, Table 1).
The lxa biosynthetic gene cluster was missing the essential
FAAL domain for the initiation of the pathway and the genes
to synthesize the modified amino acids (2S,4R)-4-OHPro,
OHMePro, O-carbamoyl homoserine, and an ABC-transporter.
The LxaA FAAL domain of S. hofmannii PCC 7110 was used as
BLASTp query to search for the initiating domain, and a FAAL
with the highest identity was annotated LxaA1 (Fig. 3, Table 1).
This gene was located 1.6 Mb upstream from the lxa biosyn-
thetic gene cluster (Fig. 3). In S. hofmannii PCC 7110, the LxaA
protein includes two domains, a FAAL and an ACP domain
(Fig. S16†). Together LxaA1 and LxaA2 act as LxaA (Fig. 3).
We predict that the cupin-like domain proteins LxaF, LxaG,
and LxaM hydroxylate Leu3, Hse8, and Aoa (Fig. 3). ORF1–3
were found in the gene cluster with no predicted function.
Eleven-residue heinamides contain the non-proteinogenic
amino acid Dhb3, the dehydration product of Thr. We discov-
ered that the condensation domain LxaC13 groups in the
modified AA clade of condensation domains that act in the de-
hydration of Thr and Ser from the previous module to Dhb or
Dha (Fig. S13†). Three putative carbamoyltransferases were
found in the genome, but none were assigned to the gene
cluster. With the lack of known carbamoyltrasferases acting on
amino acids, no reliable prediction could be made for the
enzyme responsible for the O-cabamoylation of HSe.
A set of genes encoding enzymes homologous to genes pro-
ducing (2S,4S)-4-methylproline in cyanobacterial metabolites
were identified 389 kb downstream from the lxa biosynthetic
gene cluster (Fig. 3, Table 1). These enzymes are a L-Leu
5-hydroxylase (LxaO), a zinc-binding dehydrogenase (LxaP),
and a pyrroline-5-carboxylate reductase (LxaQ) (Fig. 3, Table 1).
Flanking lxaOPQ were two genes lxaN and lxaR that encode
α-ketoglutarate-dependent oxygenases (Fig. 3, Table 1). LxaN
was discovered to have a homolog also in the S. hofmannii PCC
7110 genome 11 kb downstream of the scytocyclamide gene
cluster (WP_017742662.1). LxaN enzymes from Nostoc sp.
UHCC 0702 and S. hofmannii PCC 7110 share 93% amino acid
sequence identity. LxaN belongs to the pfam05721 class of oxy-
genases. We predicted that LxaN hydroxylates L-Pro to (2S,4R)-
4-OHPro found in heinamide and scytocyclamide structures
and that LxaR acts in OHMePro production hydroxylating the
3-carbon (Scheme 1). LxaR belongs to the pfam13640 class of
α-ketoglutarate-FeII dependent oxygenases known to hydroxy-
late amino acids.
LxaN of Nostoc sp. UHCC 0702 was heterologously
expressed in E. coli to assess if it hydroxylates L-Pro to (2S,4R)-
4-OHPro. Amino acid analysis performed with Marfey’s
method showed that a derivatized extract from E. coli with the
LxaN construct matched the retention time of derivatized
(2S,4R)-4-OHPro (Fig. 4). A control E. coli strain without added
Fig. 3 The laxaphycin (lxa) biosynthetic gene clusters and putative biosynthetic scheme in Nostoc sp. UHCC 0702. (A) Organization of predicted
heinamide biosynthetic genes. (B) Proposed biosynthetic pathway of heinamides. NRPS non-ribosomal peptide synthetase, PKS polyketide synthase,
FAAL fatty acyl AMP Ligase, ACP acyl carrier protein, KS ketosynthase, AT acyltransferase, AMT aminotransferase, C condensation domain, A adenyla-
tion domain, T thiolation domain, M methylation domain, TE thioesterase domain.
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LxaN in transformed vector did not produce a signal in LC-MS
with the corresponding mass. This confirms that hydroxylation
in (2S,4R)-4-OHPro was produced by LxaN.
Proline diversity, biosynthesis, and adenylation domain
substrate specificity
To obtain more information on laxaphycin biosynthesis,
Nostoc sp. UHCC 0702 and S. hofmannii PCC 7110 were grown
on modified media with added amino acids to determine if
the selected amino acids are incorporated into the laxaphycin
structures. The supplied amino acids were (2S,4S)-4-methyl-
proline, (2R,4R)-4-methyl-proline, (2S,4R)-4-methyl-proline,
(2S,4S)-4-hydroxyproline, (2S,4R)-4-hydroxyproline, racemic
OHLeu, and L-Leu. Changes in product structures and pro-
portions were measured with UPLC-QTOF (Fig. 5). Ten new lax-
aphycin variants were found from the cells grown on the
amino acid supplemented media (Fig. 5 and Fig. S14†).
Extracted ion chromatograms and product ion spectra of the
most abundantly produced heinamides A4 and B5 are pre-
sented in Fig. S5, S6, and S15.† Heinamides A4, A5, B6 and
scytocyclamides A3 and B5–B8 contain 4-MePro instead of
(2S,4R)-4-OHPro, OHMePro, or Pro, which are normally
present in these peptides (Fig. 1 and 5 and Fig. S14†). Addition
of (2S)-4-MePro isomers practically prevented the formation of
the original heinamide variants. Heinamide B5 is the only
4-Mepro-containing variant that was found among the original
heinamide variants (Fig. 5). The added 4-MePro stereoisomers
were not hydroxylated but incorporated as such to the struc-
ture in (2S,4S)-4-MePro and (2S,4R)-4-MePro.
Likewise, new heinamide B7 and scytocyclamide B4 pep-
tides were formed that contained OHPro stereoisomers instead
of OHMePro or Pro, but only in small amounts (Fig. S14†).
This indicates that adenylation domains that normally recog-
nize OHMePro and Pro can recognize 4-MePro much more
effectively than OHPro. Adding 4-hydroxyprolines did not
result in new 11-residue variants. Feeding with (2S,4R)-4-
OHPro (the stereoisomer naturally present in these laxaphy-
cins) prevented the formation of Pro-containing heinamides
A2 and A3 and scytocyclamide A2 so that only (2S,4R)-4-
OHPro-containing variants heinamide A1 and scytocyclamide
A were present. Feeding with L-Leu or a racemic mixture of
OHLeu did not have any effect on the synthesis of heinamides
or scytocyclamides. We tentatively hypothesized that OHLeu or
Leu would be intermediates in the biosynthesis of OHMePro.
However, supplementing the bacteria with these amino acids
did not change OHMePro levels.
Discussion
Twenty-four laxaphycin structures have been described in the
literature with antifungal, antiproliferative, and antibacterial
activities7–12,27–38 (Table S1†). Here we report eight new laxa-
phycin variants, which we call heinamides. The 12-residue hei-
namides have unique substructures compared to known laxa-
phycins: OHMePro10, OH-Aoa (5-hydroxyl β-amino octanoic
acid)1, and O-carbamoyl-homoserine4 (Table S1†). OHMePro is
an unusual amino acid in peptides. In cyanobacteria, it has
been described in nostopeptins where the hydroxyl group is
esterified by the C-terminal carboxyl group to form a macro-
cyclic peptide structure.39 OHMePro is more common in
fungal natural products, such as the clinically used antifungals
echinocandins.40 The O-carbamoyl-homoserine appears to be
a very unusual structure, as we did not find other O-carbamoyl
homoserine-containing peptides or macrocyclic peptides con-
taining O-carbamoylated amino acids in the literature. In
banyaside A, the O-carbamoyl group in glucose showed
Scheme 1 Biosynthesis of (2S,4R)-4-OHPro and OHMePro. (A)
Function of L-proline hydroxylase LxaN. (B) Proposed pathway for
OHMePro formation in heinamide biosynthesis. It was not determined if
the 3-hydroxylation catalyzed by LxaR occurs before or after the for-
mation of the heterocycle. LxaR does not hydroxylate the 3-carbon of
4-methyl proline.
Fig. 4 Amino acid analysis of LxaN construct. Retention times (min) of
Marfey-derived (with 1-fluoro-2-4-dinitrophenyl-5-L-alanine amide)
reference hydroxyproline amino acids and (2S,4R)-4-OHPro from
E. coli-LxaN extract of extracted ion chromatogram peaks from proto-
nated compounds (m/z 384.11 ± 0.1).
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156.5 ppm carbonyl and 6.45 ppm NH2 proton signals,
41
which are practically identical with O-carbamoyl-homoserine4
O-carbamoyl signals. The adenylation domain binding pocket
AA residue sequences of Hse4 (LxaI13) and cHse
8 (LxaJ11) are
identical (DLKNFGSDVK) (Table S12†) and we predict that the
substrate for both is Hse, and the carbamoylation occurs at a
later stage. While 3-aminooctanoic acid is common in laxaphy-
cins, the hydroxylated amino octanoic acid of major heina-
mide variants is a novelty. Heinamides also include other non-
proteinogenic amino acids characteristic to laxaphycins, such
as E-Dhb3 and (2S,4R)-4-OHPro4,10 in 11-residue variants and
OHLeu3 and NMe-Ile7 in 12-residue variants. The 3-OHHse8 of
12-residue heinamides is structurally identical to 4-hydroxy
threonine8 of lobocyclamides B and C.31 In the light of genetic
information on the adenylation domain substrate specifcity we
decided to refer to it as Hse. We suggest that the reported
4-OHThr8 in lobocyclamides also originates from Hse which is
3-hydroxylated. This observation means that hydroxylation in
the position-8 amino acid is C-3 specific, as this is the case in
all 24 variants of 12-residue laxaphycins described.
Heinamides share the strong synergistic antifungal activity of
laxaphycins between 11- and 12-residue variants (Fig. 2).
The general organization of laxaphycin biosynthesis for scy-
tocyclamides was described recently.10 The heinamide biosyn-
thetic gene clusters of Nostoc sp. UHCC 0702 and S. hofmannii
PCC 7110 have a very similar NRPS domain organization
(Fig. S16†). However, there are several differences in the organ-
ization of the genes between the strains (Fig. S16†). In
S. hofmannii PCC 7110, the 11-residue laxaphycin NRPSs lxaC
and lxaD are located before the 12-residue genes lxaI-L. In
Nostoc sp. UHCC 0702, the order is reversed (Fig. S16†). There
is also a difference in how the modules are organized at the
gene level. In 11-residue heinamide NRPSs, all modules are in
a single gene lxaC1, whereas in S. hofmannii PCC 7110 they are
in two genes lxaC and lxaD. In 12-residue laxaphycin NRPSs,
the modules are organized differently in the three ORFs as
shown in Fig. 3. A rearrangement of genes appears to have
occurred with probable gene fusions or fissions with the NRPS
genes altering their length. Both lxa biosynthetic gene clusters
include the PKS genes lxaB and lxaE, which are predicted to
elongate an initiating hexanoic acid to octanoic acid (Fig. 3).
The hexanoic acid was predicted to be loaded by LxaA.10 LxaA
is a two-domain enzyme with a FAAL and an ACP domain. The
heinamide biosynthetic gene cluster does not encode a direct
LxaA homolog and the biosynthetic gene cluster lacks genes
that encode FAAL (Fig. 3). However, a homolog to the ACP part
of the LxaA protein is found in the heinamide biosynthetic
gene cluster and annotated as LxaA2 (Fig. 3). A matching
homolog to the FAAL was found in the genome and is pre-
dicted to initiate biosynthesis of heinamides. This homolog
was annotated as LxaA1 (Fig. 3, Table 1). A similar situation
has been described in biosynthesis of the lipopeptides puwai-
naphycins, where some gene clusters have a PuwI enzyme with
both FAAL and ACP domains initiating biosynthesis and some
have separate FAAL (PuwC) and ACP (PuwD) genes responsible
for initiation.42
The amino acid feeding experiment demonstrated that the
adenylation domains recognizing Pro are not highly specific
and accepted all tested 4-MePro stereoisomers (Fig. 5 and
Fig. S14†). The presence of heinamide B5 suggests that
(2S,4R)-4-MePro was present in the cells without feeding but
only in minuscule amounts. The fed 4-MePros were incorpor-
ated in the peptides in non-hydroxylated form (Fig. 5), which
suggests that none of the 4-MePro is an intermediate in bio-
synthesis of OHMePro.
The branching of the biosynthetic pathway of lxa biosyn-
thetic gene cluster in heinamide and scytocyclamide biosyn-
thesis is unusual.10 This kind of branching in PKS-NRPS bio-
synthesis has also been reported with the cyanobacterial
natural products vatiamides, where a single PKS cassette has
three separate NRPS partner pathways and multiple pro-
ducts.43 This kind of genetic organization could be even more
widespread in cyanobacteria and should be considered when
identifying new biosynthetic gene clusters. The location of hei-
namide genes lxaA1HNOPQR in relation to the gene cluster is
also unusual. Typically, all genes participating in the synthesis
of a NRPS/PKS product are located directly in the gene
cluster.44 However, in this case, the biosynthesis of heina-
Fig. 5 Heinamide amounts (sum of single and double protonated and sodiated peak areas) in methanol extracts of cells grown in modified media
with added amino acids. Heinamide chemical variants and bars marked with blue and red are novel (B5 considerably increased) variants containing
added amino acids.
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mides could not be explained by genes encoded in the lxa bio-
synthetic gene cluster alone. Examples exist of crosstalk
between gene clusters located in different parts of genome.45
The co-localization of the five OHMePro and (2S,4R)-4-OHPro
tailoring genes lxaNOPQR suggests that they have a common
function and target in the cell, which assisted in functional
prediction. LxaN is also found in the S. hofmannii PCC
7110 genome, where it is also separated from the core gene
cluster. The predictions made here are the most probable
explanations for the biosynthesis of the elucidated structures,
even when the scattering of the genes through the genome
seems unconventional.
The predicted L-Pro hydroxylase activity of LxaN was con-
firmed through heterologous expression of the lxaN gene in
E. coli (Scheme 1, Fig. 4). The enzyme is encoded by both the
Nostoc sp. UHCC 0702 and S. hofmannii PCC 7110 genomes.
Hydroxyprolines are important in the pharmaceutical industry
and are produced through enzymatic reactions.46–49 (2S,4R)-4-
OHPro is used in the production of carbapenem
antibiotics50,51 and the anti-inflammatory agent oxaceprol.52
In human physiology, (2S,4R)-4-OHPro has a role in increasing
collagen stability and has been shown to facilitate collagen
biosynthesis in rats53 and is used in skin care products as Pro-
(2S,4R)-4-OHPro dipeptides.54 (2S,4R)-4-OHPro can also be
used in production of polymer materials based on polythioe-
sters.55 Hydroxylated and methylated proline have been pre-
viously described in natural products and specific enzymes
have been shown to produce these derivatives.46,56,57
3-Hydroxy-4-methylproline (OHMePro) appears in several
antimicrobial compounds, such as echinocandins, and is pro-
posed to potentiate their activity.58 In vitro synthesis strategies
have been developed for the production of OHMePro.58 In hei-
namides, OHMePro is present in variants B1 and B4, which
together are the dominant 12-residue heinamides produced by
this strain (Fig. 1). We propose that the OHMePro is syn-
thesized by a group of four enzymes lxaO-R (Scheme 1). Three
of these genes, lxaO-Q, are homologs to known cyanobacterial
methylproline synthetic enzymes59 as in nostopeptolides,60
nostocyclopeptides,61 spumigins,62 and pseudoaeruginosins.63
The fourth gene is a putative 2OG-Fe(II)-dependent oxygenase
lxaR, which 3-hydroxylates one of the methylproline intermedi-
ates but not the completed methylproline (Scheme 1). lxaR is
related to the prolyl and lysyl hydroxylase family of AlkB,
EGL-9, and leprecan. This class of enzymes is characterized as
hydroxylating oxygenases, with prolyl 3- and
4-hydroxylases.64,65 4-MePro in heinamide B5 may be a bypro-
duct, where LxaOPQ have acted without lxaR, leaking some
4-MePro to the cell. The biosynthesis of OHMePro in echino-
candin variants pneumocandins has been described, where a
α-ketoglutarate-FeII dependent enzyme GloF acts hydroxylating
OHMePro, using MePro as substrate.66–68 The methylproline
substrate is synthesized using Leu as starting point like in cya-
nobacterial MePro biosyntheses.67 GloF also hydoxylates Pro to
4-OHPro and 3-OHPro.66,68 No homolog to GloF could be
found in Nostoc sp. UHCC 0702 genome. As we showed in the
amino acid feeding experiment MePro is not used as substrate
in OHMePro biosynthesis for laxaphycins, which shows that
laxaphycin and pneumocandin OHMePros have different bio-
synthetic origins. We compared the OHMePro recognizing ade-
nylation domain of LxaK12 to OHMePro adenylation domains
in described echinocandin (BGC accession numbers KE145356
and JX421684).69,70 Both fungal adenylation domains had sub-
strate binding pocket sequence identical to each other
(DNTMITAMSK) with only 30% identity to the Lxa binding
pocket (DVQFIAHAAK). A low similarity is however expected,
as fungal adenylation domains differ from bacterial domains
and the same training data is generally not used in the predic-
tion of bacterial and fungal adenylation domain substrate
specificities.71,72
The heinamide biosynthetic gene cluster contains three
cupin domains (Fig. 3). We predict that two cupins hydroxylate
the hydroxylated amino acids in positions 3, 5, and 8 in
12-residue heinamides and scytocyclamides. We predict that
the third cupin domain unique for the heinamide cluster
hydroxylates Aoa1, which is not hydroxylated in scytocycla-
mides.10 The adenylation domain binding pocket sequences
for 3-OH-D-Leu and D-Leu are identical (DAWFLGNVVK)
(Table S12†). This suggests that both domains identify the
same substrate, and they both are predicted to recognize Leu.
Both modules also have an epimerase domain, so stereospeci-
ficity does not explain the difference in hydroxylation. From
this we conclude that the hydroxylation happens at a later
stage. It is possible that the hydroxylation occurs as Leu is
bound to the PCP or after the peptide is released. In the
reported 12-residue laxaphycins Leu3 is always hydroxylated
and Leu5 has hydroxylated and non-hydroxylated variants,
with the exception of lyngbyacyclamides and heinamides
(Table S1†). We propose, that a single cupin enzyme hydroxyl-
ates both leucins on the released peptide, with poorer affinity
on Leu5. We also suggest that Leu5 in heinamides is not
hydroxylated because structurally divergent cHse4 blocks the
enzyme from interacting with the Leu5 residue. Although a pre-
vious article on laxaphycins predicted that the hydroxylation is
performed by cytochrome p450 enzymes,36 we did not find
these enzymes in the genomes of S. hofmannii PCC7110 or
Nostoc sp. UHCC 0702. Thr dehydration to Dhb by the conden-
sation domain of the modified AA clade has been shown
experimentally in the biosynthesis of albopeptide.73 The con-
densation domain LxaC13 following the Thr incorporation
module was found to belong this clade, as shown in phyloge-
netic studies10,74 (Fig. S13†).
Conclusions
In this study we characterized heinamides, which are new laxa-
phycin variants with several new modifications that possess
antifungal activity, which is synergistic between the 11- and
12-residue compounds. These new laxaphycins broaden the
known chemical space of bioactive natural products and
provide new insight to potentially useful building blocks in
antimicrobial molecules. We also describe the heinamide bio-
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synthetic pathway, propose pathways for the amino acid modi-
fications, and show experimentally the function of the proline
hydroxylase LxaN. The synthesis of (2S,4R)-4-OHPro and
OHMePro are of interest because their biosynthetic origins
have been described in other organisms such as fungi but not
in cyanobacteria.
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